Abstract. Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and accounts for ~80% of all kidney cancer cases. However, the pathogenesis of RCC has not yet been fully elucidated. To interpret the pathogenesis of RCC at the molecular level, gene expression data and bio-informatics methods were used to identify RCC associated genes. Gene expression data was downloaded from Gene Expression Omnibus (GEO) database and identified differentially coexpressed genes (DCGs) and dysfunctional pathways in RCC patients compared with controls.
Introduction
Kidney cancer that forms in tissues of the kidney is not a single disease, instead it comprises a number of different types of cancer of which renal cell carcinoma (RCC) is the most common type in adults, responsible for ~80-90% of cases (1, 2) . The diagnosis of RCC is a challenging and difficult task, and RCC is one of the most therapy-resistant types of cancer. RCC is regarded as a highly lethal cancer and ~35% of patients succumb to the disease after 5 years (3) .
Understanding the pathogenesis and biological mechanism of RCC may improve the current diagnosis, treatment and prognosis of RCC. However, the pathogenesis of RCC is extremely complex and remains to be fully elucidated. Smoking, obesity and mutations in specific genes increase the risk of developing RCC (4) (5) (6) . The best characterized oncogenic gene in human RCC is the tumor suppressor gene von Hippel-Lindau (VHL). VHL along with elongin B, elongin C and cullin 2 form a E3 ubiquitin-ligase complex, and are considered to serve an important role in RCC (7, 8) . The VHL complex targets hypoxia-inducible factor (HIF) for ubiquitin-mediated degradation (9) . Mutations in VHL can result in the over accumulation of HIF, and its target genes such as VEGF (vascular endothelial growth factor), PDGF (platelet derived growth factor) and EGRF (epidermal growth factor receptor), thus resulting in carcinogenesis (10) (11) (12) . Mutations of either tuberous sclerosis 1 (TSC1) or TSC2 are associated with aberrant activation of mammalian target of rapamycin (mTOR) pathway, which increases the risk of RCC (13, 14) . Owing to the above reasons, VEGF, PDGF, EGRF and mTOR may serve as potential target molecules for the treatment of RCC. In addition, dysregulation of membrane MHC class I chain-related gene A (MICA), cyclooxygenase-1 (COX1), TGF-β-activated Kinase-1 (TAK1), and cell division cycle 25B (CDC25B) serve critical roles in RCC progression (15) (16) (17) (18) . Previous studies have predominantly focused on single genes, and paid little attention to the dysregulation of transcription factors or differentially coexpressed genes; therefore the present study aimed to address this issue to provide novel insights into RCC.
DNA microarray has previously been used to identify gene expression patterns in RCC (19, 20) . In order to achieve a more comprehensive understanding of the molecular mechaIdentification of genes associated with renal cell carcinoma using gene expression profiling analysis 
Materials and methods
Affymetrix microarray data. The gene expression profile dataset GSE6344 (21), including 10 RCC samples and 10 patient-matched normal control samples, was obtained from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih. gov/geo/) database. The probe-level data was converted into the corresponding gene symbol using the annotation information derived from platform GPL96. For genes corresponding with multiple probe sets that had multiple expression values, the mean expression values of those probe sets were obtained. As a result, 12,754 genes were obtained from this dataset.
Construction of regulatory network. The data of TF binding sites of human genome hg18 and the coordinates of genes were downloaded from UCSC (http://genome.ucsc.edu). TF binding sites within the area from 1 kb upstream to 0.5 kb downstream of the transcription initiation site of target genes were selected to construct the regulatory network.
Differentially coexpressed genes analysis. For any pair of genes (X,Y), the absolute difference (Diff) of the Pearson's correlation coefficient in the normal state (P-normal) and in the cancer state (P-tumor) was calculated. The pair of genes was regarded as DCGs only when their Diff was >1. Diff value >1 indicated that the pair of genes had a negative correlation (P-normal ∈ [-1,0] ) and a positive correlation (P-tumor ∈ [0,1]) under the normal and tumor state respectively, or vice versa. The difference was calculated using the following equation 1: Diff=abs (r1 ij -r2 ij ). In this equation, r1 ij and r2 ij indicate the Pearson correlation coefficients between gene i and gene j under the normal state and the state of cancer, respectively. (22) , which is a robust and effective methodology to identify the regulatory impact factor of TF, was applied to identify the TF with the largest contribution to differential expression of genes in two biological conditions. RIF was calculated using the following equation 2:
Measurement of RIF. Regulatory impact factors (RIF)
In this equation, n de is the number of DEGs; e1 j and e2j indicate the expression value of the DEG in conditions 1 and 2, respectively; r1 ij and r2 ij indicate the correlation coefficient for the i TF and the j DEG in conditions 1 and 2, respectively.
Pathway enrichment analysis.
For functional analysis of the large gene lists in the regulatory network, the DCGs were inputted into Database for Annotation, Visualization and Integrated Discovery (DAVID) (23) for Kyoto Encyclopedia of Genes and Genomes (KEGG) (24) pathway enrichment analysis. By calculating the hypergeometric test P-value for probability of random association between a given list of genes and a pathway, DAVID identifies canonical pathways associated with this set of genes. FDR <0.05 was used as the cutoff criteria.
Results

Identification of differentially coexpressed genes in RCC.
The gene expression profile dataset GSE6344 was downloaded from the GEO database and formula 1 was used to identify DCGs with Diff >1 between 10 RRC samples and 10 control samples. Finally, a total of 2,580,427 DCGs were screened out (Table I) .
Construction of regulatory network. Based on the known regulatory data from UCSC, TFs and their corresponding target genes from DCGs were selected to construct a regulatory network. The network contained a total of 1,525 pairs of regulatory associations between 126 TFs and 1,259 target genes. Using Cytoscape (25) , the regulatory associations were integrated and visualized in Fig. 1 .
KEGG pathway enrichment. The DCGs with FDR <0.05 were inputted into DAVID for KEGG pathway enrichment analysis. The results are presented in Table II , from which it was identified that DCGs were predominantly enriched in cancer pathways, ErbB, mitogen-activated protein kinase (MAPK) and other important pathways. Analysis of transcription factor impact. First, total 4,793 differentially expressed genes (DEGs) with FDR <0.05 were identified between normal and tumor samples by linear models for microarray data (limma) method (26) . Subsequently, 469 overlapping DEGs were collected by comparing these 4,793 DEGs with the 1,259 target genes in the network. To further investigate which TFs were significant, the RIF of each TF targeting to the overlapping DEGs was targeted. The top 10 were forkhead box C1 (FOXC1), GATA-binding protein 3 (GATA3), estrogen receptor 1 (ESR1), FOXL1, POZ (BTB) and AT hook containing zinc finger 1 (PATZ1), v-myb avian myeloblastosis viral oncogene homolog (MYB), signal transducer and activator of transcription 5A (STAT5A), early growth response 2 (EGR2), EGR3 and proline, glutamate and leucine rich protein 1 (PELP1) ( Table III) . Of these TFs, GATA3, MYB, EGR2, and EGR3 have previously been identified to be associated with RCC and the regulatory associations of them with their targets are presented in Fig. 2 . Occurrence of RCC is likely caused by the abnormal changes of these regulatory associations. 
Discussion
Molecular biomarkers are useful to improve diagnosis, clinical predictive capability and novel therapeutic efficacy. Because the emergence of microarray technology makes it possible to investigate the expression levels of thousands of genes simultaneously (27) , it has been widely used in discovery of disease biomarkers (28) (29) (30) . However, the majority of previous studies are based on a single gene differential expression analysis. In the current study, differentially coexpressed genes analysis was used to find the dysregulated gene pairs in RCC. The differentially coexpressed genes analysis provides novel analytical perspective to studies including identification of differentially coexpressed genes and marker genes of disease, construction of differential coexpression network and analysis of module (31, 32) . Besides, a regulatory network was constructed and the RIF score of each TF targeting to the DEGs with FDR <0.05 was calculated. Finally, the top 10 ranked TFs were identified which were FOXC1, GATA3, ESR1, FOXL1, PATZ1, MYB, STAT5A, EGR2, EGR3 and PELP1. They may be potential molecular biomarkers of RCC. FOXC1 is one of the forkhead transcription factor family, which is characterized by a unique DNA-binding domain. Although the specific function of this gene has not yet been determined, it is known that the gene is associated with the occurrence of a number of types of cancer, such as breast cancer, lung cancer, prostate cancer, bile duct cancer (33) (34) (35) (36) ). FOXC1 appears to be a cancer-associated gene. FOXL1 and FOXC1 belong to the same family and have similar functions. So these genes may serve important roles in the pathogenesis of RCC.
The transcription factor encoding by GATA3 belongs to the GATA family, and it contains two GATA-type zinc fingers which serve an important role in regulating T cell development and the biology of endothelial cell. Cooper et al (37) demonstrated that GATA3 was methylated in clear cell RCC patients and its mRNA expression level was downregulated in all stages of clear cell RCC (37) , which indicated the critical role of GATA3 in RCC.
As an estrogen receptor, ESR1, which contains a number of important structural domains such as the DNA-binding domain, transcriptional activation domain and hormone binding domain, is a TF activated by its corresponding ligand. It is known that ESR1 serves an important role in breast cancer (38) . Although it has not yet been reported that this gene is associated with RCC at present, it is likely to be a potential factor because its RIF ranks third.
Among PATZ1, MYB, STAT5A, EGR2/EGR3 and PELP1, it is known that MYB and EGR2/EGR3 (39) are RCC associ- ated genes, and the PATZ1, STAT5A and PELP1 are hormone associated genes. The latest article reported that hormones may inhibit the occurrence of renal carcinoma (40) , so that PATZ1, STAT5A and PELP1 may serve as potential renal cancerassociated genes. Table II identifies genes of the regulatory network which were enriched in various cancer pathways, just as the above discussion that the top 10 TFs were involved in a number of types of cancers. In addition, ErbB and MAPK pathways were overrepresented. The MAPK signaling pathways serve vital roles in cell proliferation and differentiation. Recently, Huang et al (41) reported that suppression of one or more MAPK signaling pathways by inhibitor of MAPK kinases (MKKs) reduced RCC cell proliferation in vitro and inhibited RCC growth in vivo. The ErbB protein family is a family containing 4 structurally associated receptor tyrosine kinases, ErbB1 (also termed EGFR), ErbB2, ErbB3 and ErbB4. ErbB signaling pathway has been implicated in the development of a wide variety of types of tumor, including RCC (42, 43) . Further analysis of these pathways will contribute to an improved understanding of the roles of the differentially expressed genes and the underlying molecular mechanism of RCC.
In conclusion, the present study used microarray gene expression profiling and regulatory network analysis to explore the molecular mechanism of RCC. The top 10 ranked TFs were identified, which were FOXC1, GATA3, ESR1, FOXL1, PATZ1, MYB, STAT5A, EGR2, EGR3 and PELP1. GATA3, ERG and MYB are considered RCC associated genes while FOXC1, ESR1, FOXL1, PATZ1, STAT5A and PELP1 may also be potential genes associated with RCC. The present study indicates that the above TFs may be used as biomarkers of RCC for accurate diagnosis, prognosis or as predictive markers for treatment efficiency. However, further experiments are needed to confirm these result.
